Payment overview · 2025
General Payments
$2,816.25
29 reported records · 8 companies
Healthcare provider profile · identity verified
Anit B. Patel, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · FAIRFIELD, CA · NPI 1982646154
Verified facts
What the public records show
CMS Open Payments records show Anit B. Patel, M.D. received $2,816.25 in general payments during 2025 across 29 reported records.
Inspire Medical Systems, Inc. accounted for 64.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ofev.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OFEV as an associated drug or biological on 14236 records involving 6873 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Ofev by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $1,813.96 | 64.4% | 12 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $257.66 | 9.2% | 3 | 2025 |
| INTUITIVE SURGICAL, INC. | Unresolved — no canonical attribution shown | $191.74 | 6.8% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $178.62 | 6.3% | 3 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $153.82 | 5.5% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $124.87 | 4.4% | 1 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $61.75 | 2.2% | 2 | 2025 |
| Medical Device Business Services, Inc. | Unresolved — no canonical attribution shown | $33.83 | 1.2% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,431.82 | 24 |
| Travel and Lodging | $1,294.44 | 4 |
| Education | $89.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $1,813.96 | 12 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $257.66 | 3 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $257.66 | 3 | 2025 |
Source payment records
|
|||||
| Da Vinci Surgical System Normalized: da vinci surgical system |
Device | INTUITIVE SURGICAL, INC. | $191.74 | 3 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $153.82 | 3 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $146.36 | 2 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $124.87 | 1 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $61.75 | 2 | 2025 |
Source payment records
|
|||||
| Monarch Normalized: monarch |
Device | Medical Device Business Services, Inc. | $33.83 | 2 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $32.26 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| OFEV ofev |
2025 | Ofev | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | OFEV open payments reported associated product |
CMS Open Payments — General Payments 14236 supporting records · 6873 recipient NPIs · example record 1221811762 |
Ofev · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Albuterol Sulfate Hfa | Albuterol Sulfate | 219 | 90 |
| Spiriva Respimat | Tiotropium Bromide | 188 | 45 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 118 | 23 |
| Incruse Ellipta | Umeclidinium Bromide | 98 | 23 |
| Arnuity Ellipta | Fluticasone Furoate | 95 | 25 |
| Prednisone | Prednisone | 94 | 36 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 85 | 17 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 70 | 22 |
| Ventolin Hfa | Albuterol Sulfate | 66 | 22 |
| Montelukast Sodium | Montelukast Sodium | 60 | 22 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 58 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 54 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 53 | 17 |
| Symbicort | Budesonide/Formoterol Fumarate | 53 | 11 |
| Armodafinil | Armodafinil | 36 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 36 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 34 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 34 | 11 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 28 | 12 |
| Qvar Redihaler | Beclomethasone Dipropionate | 28 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 26 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 24 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 22 | suppressed |
| Ofev | Nintedanib Esylate | 20 | suppressed |
| Azithromycin | Azithromycin | 18 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Dulera | Mometasone/Formoterol | 16 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 14 | suppressed |
| Roflumilast | Roflumilast | 14 | suppressed |
| Rifampin | Rifampin | 13 | suppressed |
| Tadalafil | Tadalafil | 13 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 12 | suppressed |
| Zaleplon | Zaleplon | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,816.25 · 29 records | Inspire Medical Systems, Inc. | Arikayce, Da Vinci Surgical System, INSPIRE, JASCAYD, Monarch, OFEV, OPSUMIT, Ohtuvayre, TAVNEOS, UPTRAVI | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ofev play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error